Maitake and Cardiovascular Risk Reduction

Maitake and Blood Pressure / Cardiovascular Health

4 independent cardiovascular mechanisms

Research spanning 2001 to 2024 documents four separate biological pathways through which Grifola frondosa acts on cardiovascular risk, each operating through distinct biology and each with its own body of evidence.

Journal of Functional Foods, 2024

HMGCR suppressed

rate-limiting cholesterol synthesis enzyme downregulated in liver proteomic analysis (Ding et al., 2016)

CYP7A1 upregulated

cholesterol-to-bile-acid conversion gene activated in two independent maitake studies

7 prospective studies

covered in the 2021 systematic review linking mushroom consumption to better cardiovascular biomarkers

Journal of Functional Foods, 2024

View as image ↗

A 2021 systematic review pulled together seven prospective studies on mushroom consumption and heart health. Across those studies, people who ate more mushrooms had better cardiovascular biomarkers: more favorable lipid profiles, lower blood pressure, lower inflammatory markers.^[2] The pattern was consistent enough that a 2023 follow-up human cardiometabolic review called it one of the more reliable associations in the nutrition-cardiovascular literature.^[3]

But those studies ask about mushrooms generally, mixing every species across every dinner table. The more specific question is: what does maitake do, at the cellular and molecular level, to affect cardiovascular risk?

Grifola frondosa supports cardiovascular health through four documented biological pathways: cholesterol regulation via liver gene expression changes, reduction of atherosclerotic plaques via LDL oxidation inhibition, endothelial protection via adhesion molecule suppression, and blood pressure reduction via ACE inhibition and renin-angiotensin system modulation. All evidence is from animal and cell studies. No human randomized controlled trial has tested maitake for cardiovascular outcomes specifically.

This article examines each pathway separately, because they operate through distinct biology and the evidence for each stands on its own. For the foundational overview of what maitake is and what it contains, see the complete guide to maitake mushroom.

Mushroom Eaters Have Better Heart Biomarkers: What the Population Data Shows

The population-level story starts with a 2019 prospective cohort study by Zhang and colleagues. They tracked mushroom consumption against cardiovascular biomarkers in US women and men over time. People who ate more mushrooms had lower total cholesterol and lower C-reactive protein, a blood marker of inflammation that cardiovascular researchers use to gauge arterial risk.^[1]

The 2021 Krittanawong systematic review expanded this picture. Pulling together seven prospective studies through 2020, the authors found consistent associations between mushroom consumption and favorable changes in both lipid profiles and blood pressure. Their conclusion: mushroom consumption shows "potential health benefit" for cardiovascular health. That framing is deliberately cautious. These are observational studies, and observational studies identify patterns rather than causes.^[2]

The most current human-focused analysis comes from Zamora-Ros and colleagues in 2023. Their systematic review covered both observational and interventional studies on mushroom consumption and cardiometabolic risk. Across the evidence base, mushroom intake was associated with improvements in blood pressure, lipid profiles, and cardiometabolic risk biomarkers. The authors were careful about causal language: the evidence points in a consistent direction, but association and causation are different things.^[3]

None of these studies isolates maitake. They ask whether people who eat mushrooms broadly tend to have better cardiovascular biomarkers. The answer, consistently, is yes. The question of what maitake specifically does in the body requires looking at preclinical research, where individual species and specific mechanisms can be tested directly.

For the role of mushroom-specific antioxidants in cardiovascular protection, see ergothioneine and cardiovascular disease.

How Maitake Turns Down the Cholesterol Factory: Gene Regulation in the Liver

The cholesterol story in maitake research runs from 2001 to 2016, with each study adding a layer of mechanistic detail to the one before it.

Fukushima and colleagues (2001) fed rats a high-cholesterol diet with or without maitake fiber supplementation. The maitake group had lower serum total cholesterol, lower LDL cholesterol, and a better total cholesterol-to-HDL ratio. The mechanism was physical: maitake fiber enhanced fecal cholesterol excretion. More cholesterol was leaving the body through the gut rather than entering the bloodstream.^[4]

Sato and colleagues (2013) went a level deeper. In cholesterol-fed mice, dietary maitake lowered plasma total cholesterol and also changed gene activity in the liver. Two specific genes shifted in a cholesterol-lowering direction: CYP7A1 was turned up, and ACAT2 was turned down.^[5]

CYP7A1 is the enzyme that converts cholesterol into bile acids inside the liver. It is the primary route by which the body clears excess cholesterol. When CYP7A1 activity increases, more cholesterol gets converted and excreted through bile. ACAT2 works in the opposite direction: it converts free cholesterol into a stored form called cholesterol esters. When ACAT2 activity decreases, less cholesterol accumulates in storage.

Ding and colleagues (2016) provided the molecular precision that ties the earlier studies together. Using proteomic analysis, a technique that simultaneously measures hundreds of proteins in a tissue sample, they found 20 differentially expressed proteins in the livers of maitake-fed rats compared to controls.^[6]

Among those 20 proteins, HMGCR was suppressed. HMGCR is the rate-limiting enzyme in cholesterol synthesis inside the liver. It is the molecular bottleneck that controls how much cholesterol the liver makes from scratch, and it is the same enzyme that statin drugs block. Ding also confirmed the Sato findings: CYP7A1 was up and ACAT2 was down. Additionally, ApoB, the main protein that packages cholesterol into LDL particles for transport through the blood, was reduced.

Across all three studies, dietary maitake appears to push the liver toward making less cholesterol (HMGCR down), converting more existing cholesterol to bile acids for excretion (CYP7A1 up), storing less cholesterol (ACAT2 down), and packaging less cholesterol into LDL for circulation (ApoB down). The fiber-excretion route Fukushima found and the gene-regulation route Sato and Ding found are complementary mechanisms pointing in the same direction.

Smaller Plaques in the Arteries: What Happened in Atherosclerosis-Prone Mice

Atherosclerosis is the buildup of fatty deposits inside artery walls that underlies most heart attacks. Lowering circulating cholesterol is relevant to atherosclerosis, but it is indirect evidence. The 2008 Wei study tested whether maitake affected plaque formation directly.

Wei and colleagues used apoE-knockout mice, the standard animal model for atherosclerosis research. These mice carry a genetic deletion that disables apolipoprotein E, a protein the body uses to clear cholesterol from the blood. Without it, cholesterol accumulates and the animals develop arterial plaques even on a normal diet. They are the closest available animal approximation of human atherosclerotic disease that can be tested in a controlled setting.

After dietary Grifola frondosa supplementation, maitake-fed mice had smaller atherosclerotic lesions in their arteries compared to control animals. Two molecular changes in artery wall tissue appeared to drive the protective effect.^[7]

First, maitake inhibited LDL oxidation. This matters because oxidized LDL is far more damaging than ordinary LDL. Once LDL cholesterol is oxidized by free radicals in the artery wall, it triggers inflammatory responses and is readily taken up by the immune cells (macrophages) that form the core of atherosclerotic plaques. Maitake appeared to interfere with that oxidation step before the cascade begins.

Second, maitake shifted the protein balance in artery wall cells in a protective direction. HSP60, a heat shock protein associated with inflammatory signaling in atherosclerosis, was down-regulated. Prdx-1, a peroxiredoxin enzyme that protects cells against oxidative damage, was up-regulated. Both changes are consistent with reduced plaque progression.

This was the first study to test maitake in a direct atherosclerosis model, rather than just measuring lipids in circulation. It added a second mechanism, one that operates at the site of plaque formation rather than in the liver or gut.

For the broader connection between mushroom antioxidants and atherosclerosis prevention, see ergothioneine and atherosclerosis prevention.

Blocking the Cellular Handshake That Starts Arterial Plaque Formation

Atherosclerotic plaque does not begin with cholesterol depositing directly in the artery wall. It begins with an adhesion event: immune cells circulating in the blood must first attach to the inner surface of the artery. This adhesion is mediated by proteins called adhesion molecules, which are displayed on artery wall cells (endothelial cells) and serve as docking points. Once circulating monocytes (a type of immune cell) attach and migrate into the artery wall, they begin consuming oxidized LDL and accumulating into the fatty deposits at the core of plaques.

Martin and colleagues (2010) tested whether mushroom extracts could interfere with this upstream adhesion step. Using human aortic endothelial cells in a laboratory model, they exposed the cells to an inflammatory environment and then applied various mushroom extracts, including Grifola frondosa. They measured two specific adhesion proteins: ICAM-1 (intercellular adhesion molecule-1) and VCAM-1 (vascular cell adhesion molecule-1). Both are up-regulated during inflammation and serve as the primary docking points for circulating monocytes.^[8]

Maitake extract reduced the expression of both ICAM-1 and VCAM-1 on the artery wall cells. With fewer adhesion proteins on the surface, fewer monocytes could attach. The researchers confirmed this directly: monocyte binding to the endothelial cell layer was reduced.

This is an in vitro finding, meaning it happened in a laboratory dish rather than in a living animal or person. That is a real limitation. But the mechanism it identifies is specific and biologically meaningful: maitake compounds appear to reduce the display of the very proteins that initiate plaque formation, acting upstream of the cholesterol and oxidation events the other studies describe.

For more on endothelial function and vascular protection research on mushroom compounds, see ergothioneine and endothelial function.

Blood Pressure, Metabolic Syndrome, and the Full Cardiovascular Picture

Blood pressure regulation is the fourth cardiovascular pathway in the maitake research. The animal studies on this topic are covered in depth in the companion articles in this cluster: maitake and blood pressure research, maitake for hypertension, and ACE inhibition mechanisms. For the precise molecular mechanisms, see maitake and renin-angiotensin system modulation.

What is worth noting here is the metabolic syndrome context. High blood pressure, high cholesterol, and atherosclerosis rarely occur in isolation. They tend to cluster together in people with insulin resistance, the constellation of risk factors that researchers call metabolic syndrome. Several maitake studies tested animals with combined metabolic dysfunction, not just isolated hypertension.

The SX-fraction of maitake simultaneously lowered blood pressure and blood glucose in diabetic rats. In obese Zucker fatty rats, an animal model of metabolic syndrome, maitake fractions reduced blood pressure and improved insulin sensitivity in the same animals. This co-occurrence suggests that at least some of maitake's cardiovascular effects are mediated through metabolic pathways rather than direct cardiovascular action alone.

The 2024 comprehensive review synthesizes this perspective: maitake's cardiovascular effects are not isolated single-target actions but emerge from a broader pattern of metabolic regulation across cholesterol metabolism, blood pressure, and insulin signaling.^[9]

What Human Studies Show (and Where the Evidence Stops)

Every mechanism described above is preclinical. The population data associating mushroom consumption with better heart biomarkers (Zhang 2019, Krittanawong 2021, Zamora-Ros 2023) does not isolate maitake and does not establish causality. The animal and cell studies show consistent, mechanistically coherent effects across multiple research groups, animal models, and biological pathways. But they do not by themselves confirm human benefit.

No randomized controlled trial has tested maitake for cardiovascular outcomes in humans.

The 2023 Zamora-Ros systematic review is the most rigorous human-focused analysis available. It found consistent patterns across observational and interventional studies, with mushroom intake associated with improvements in blood pressure, lipid profiles, and cardiometabolic risk biomarkers. The authors appropriately distinguished association from causation.^[3]

The 2021 Krittanawong review settled on "potential health benefit," which is accurate language for the current state of the evidence.^[2]

The four mechanisms documented in the preclinical maitake literature are mechanistically coherent, each supported by independent evidence, and collectively consistent with the population-level associations researchers have observed. What they cannot provide, on their own, is proof of human benefit. That requires controlled human trials that have not yet been conducted for maitake cardiovascular outcomes. The preclinical evidence is genuinely informative about how maitake might work. The gap is at the top of the evidence pyramid, and it is not a small one.

The Bottom Line

The research on maitake and cardiovascular risk documents four independent biological pathways: cholesterol reduction through liver gene regulation (HMGCR suppression, CYP7A1 upregulation, ApoB reduction), reduction of atherosclerotic plaque lesions in apoE-knockout mice via LDL oxidation inhibition, endothelial protection through adhesion molecule suppression (ICAM-1, VCAM-1), and blood pressure reduction through ACE and renin-angiotensin system modulation. All mechanistic evidence is preclinical. Population data from three systematic reviews points consistently toward cardiovascular benefit from mushroom consumption broadly, but no randomized controlled trial has tested maitake specifically for cardiovascular outcomes in humans.

Frequently Asked Questions

Is maitake mushroom good for the heart?

Animal and cell studies show maitake acts on multiple cardiovascular risk pathways, including cholesterol gene regulation, atherosclerotic plaque reduction, endothelial protection, and blood pressure. Population research links mushroom consumption broadly to better heart biomarkers across seven prospective studies (Krittanawong et al., 2021). No human clinical trial has tested maitake specifically for cardiovascular outcomes, so the question of direct benefit in humans remains unanswered by controlled research.

Can maitake lower cholesterol?

In animal studies, dietary maitake lowered serum total cholesterol and LDL cholesterol through two documented routes: increased fecal cholesterol excretion via dietary fiber (Fukushima et al., 2001) and changes in liver gene expression that reduce cholesterol synthesis and increase bile acid production (Sato et al., 2013; Ding et al., 2016). The rate-limiting cholesterol synthesis enzyme HMGCR was specifically downregulated in the 2016 proteomic study. These are preclinical findings; no human clinical trial has tested this effect.

Does maitake prevent atherosclerosis?

In apoE-knockout mice, a standard atherosclerosis research model, dietary maitake reduced the size of atherosclerotic lesions in the arteries and inhibited LDL oxidation (Wei et al., 2008). A separate study found maitake extract reduced adhesion molecule expression on human aortic cells in laboratory conditions, blocking the cellular event that initiates plaque formation (Martin et al., 2010). Both findings are preclinical and have not been replicated in human trials.

What mushrooms are best for cardiovascular health?

No head-to-head human trial has compared mushroom species for cardiovascular benefit. The population studies showing improved heart biomarkers cover mushroom consumption generally and do not identify a single best species. Among individual species, maitake has one of the most developed preclinical cardiovascular research bodies, spanning cholesterol regulation, atherosclerosis, endothelial protection, and blood pressure across multiple animal models. Shiitake, reishi, and oyster mushroom also have relevant preclinical cardiovascular data.

Can maitake reduce heart disease risk?

The preclinical evidence documents four mechanisms relevant to cardiovascular risk reduction: cholesterol gene regulation, atherosclerotic plaque reduction, endothelial protection, and blood pressure modulation. A 2021 systematic review of seven prospective studies found mushroom consumption associated with favorable lipid profiles and blood pressure. A 2023 human cardiometabolic systematic review found consistent associations between mushroom intake and cardiometabolic biomarker improvements. Whether maitake specifically reduces heart disease risk in humans has not been tested in a controlled trial.

Sources & References

1. 1. Source details for this reference are not yet available.
2. 2. Source details for this reference are not yet available.
3. 3. Source details for this reference are not yet available.
4. 4. Source details for this reference are not yet available.
5. 5. Source details for this reference are not yet available.
6. 6. Source details for this reference are not yet available.
7. 7. Source details for this reference are not yet available.
8. 8. Source details for this reference are not yet available.
9. 9. Source details for this reference are not yet available.